Avanir Pharmaceuticals (AVNR) Reports In-Line Q4 Loss of 9c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Join SI Premium – FREE
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q4 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $12.9 million.
For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.
For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plexus Corp (PLXS) Tops Q4 EPS by 29c; offers guidance
- Albany International (AIN) Tops Q3 EPS by 45c; Offers Guidance
- Axis Capital (AXS) Misses Q3 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
